US Broker Ratings

Alphatec Holdings, Inc. (ATEC) Stock Analysis: A Promising 19.66% Upside in the Medical Devices Sector

Alphatec Holdings, Inc. (NASDAQ: ATEC) is capturing investors’ attention with a compelling potential upside of 19.66%, as it continues to make significant strides in the medical devices sector. Specializing in..

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: A Look at Its 194% Potential Upside

Ultragenyx Pharmaceutical Inc. (RARE), a pioneering entity in the biotechnology sector, is capturing investor attention with its remarkable 194% potential upside, according to recent analyst ratings. Specializing in the development..

LifeStance Health Group, Inc. (LFST) Stock Analysis: Strong Buy Ratings Point to 56% Upside Potential

LifeStance Health Group, Inc. (NASDAQ: LFST) is making waves in the healthcare sector, specifically within the medical care facilities industry. With a market capitalization of $2.1 billion, LifeStance is carving..

Arrowhead Pharmaceuticals (ARWR) Investor Outlook: Exploring a Biotech Pioneer with a 111% Potential Upside

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) presents a compelling opportunity in the biotechnology sector, a field known for its potential to deliver groundbreaking treatments and substantial returns for investors. With a..

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A Biotech with 99% Potential Upside

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is capturing attention in the biotechnology sector with its promising portfolio of treatments for rare diseases. The company’s market cap stands at $1.76 billion, and..

ImmunityBio, Inc. (IBRX) Stock Analysis: Unpacking a Biotech Giant’s 353% Potential Upside

ImmunityBio, Inc. (NASDAQ: IBRX), a prominent player in the biotechnology sector, has captured the attention of investors with its groundbreaking work in immunotherapy and a staggering potential upside of 353.33%...

Denali Therapeutics Inc. (DNLI) Stock Analysis: A Biotech Bet with 102% Upside Potential

Denali Therapeutics Inc. (NASDAQ: DNLI), a prominent player in the biotechnology sector, is capturing the attention of investors with its ambitious pipeline and compelling upside potential. Specializing in therapeutics for..

PTC Therapeutics, Inc. (PTCT): Analyst Consensus Reveals 35.27% Potential Upside for Biotech Innovator

PTC Therapeutics, Inc. (NASDAQ: PTCT) is carving a niche in the biotechnology sector with its focus on rare disorders. Headquartered in Warren, New Jersey, PTC Therapeutics is making significant strides..

Harmony Biosciences Holdings (HRMY) Stock Analysis: Exploring a 35% Upside Potential with Promising Clinical Developments

For investors with a keen interest in the biotechnology sector, Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) presents a compelling opportunity. This Pennsylvania-based company, with a market capitalization of $2.15 billion,..

Arcellx, Inc. (ACLX) Stock Analysis: Exploring a 65% Potential Upside in Biotechnology

Arcellx, Inc. (NASDAQ: ACLX) is making waves in the biotechnology sector, drawing significant investor attention with its promising pipeline of immunotherapies and a notable potential upside. Based in Redwood City,..

Zai Lab Limited (ZLAB) Stock Analysis: A Biotech Gem with 65% Upside Potential

Zai Lab Limited (NASDAQ: ZLAB) stands out in the biotechnology sector with its robust pipeline and strategic collaborations poised to address critical medical conditions. Headquartered in Pudong, China, this innovative..

Vericel Corporation (VCEL) Investor Outlook: Exploring a 50.53% Potential Upside

Vericel Corporation (NASDAQ: VCEL), a prominent player in the biotechnology sector, is capturing investor attention with its remarkable potential upside of 50.53%, as indicated by recent analyst ratings. Headquartered in..

HUTCHMED (China) Limited (HCM)

⚠️ No article content returned.

..

Apogee Therapeutics, Inc. (APGE) Stock Analysis: Exploring a 161.91% Potential Upside in the Biotech Arena

Apogee Therapeutics, Inc. (NASDAQ: APGE) is capturing the attention of investors, offering a noteworthy potential upside of 161.91% based on its average analyst target price. With a market capitalization of..

CRISPR Therapeutics AG (CRSP) Stock Analysis: Exploring a Potential 51.49% Upside in Gene Editing

CRISPR Therapeutics AG (NASDAQ: CRSP) is at the forefront of the gene-editing revolution, providing investors with a unique opportunity to tap into groundbreaking advancements in biotechnology. The company, headquartered in..

Warby Parker Inc. (WRBY) Stock Analysis: A Promising Player in the Healthcare Sector with Strong Analyst Support

Warby Parker Inc. (NYSE: WRBY), a prominent name in the healthcare sector specializing in medical instruments and supplies, has carved a niche in the eyewear market with its innovative approach..

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: Navigating Challenges with a Promising 17% Upside Potential

DENTSPLY SIRONA Inc. (XRAY), a titan in the healthcare sector specializing in medical instruments and supplies, is managing a complex landscape of opportunities and challenges. With a market capitalization of..

Sotera Health Company (SHC) Stock Analysis: Navigating Growth with a 6.4% Revenue Surge in the Healthcare Sector

Sotera Health Company (NASDAQ: SHC), a prominent player in the healthcare diagnostics and research industry, is capturing investor attention with its steady revenue growth and strategic market positioning. With a..

ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: Navigating a Promising Upside with CNS Innovations

Investors with a keen eye on the healthcare sector may find ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) an intriguing prospect, particularly given its promising position within the biotechnology industry. With a..

Soleno Therapeutics, Inc. (SLNO): Investor Outlook on Potential 72.96% Upside in Biotech

Soleno Therapeutics, Inc. (NASDAQ: SLNO), a burgeoning name in the biopharmaceutical sector, is attracting considerable attention from investors, especially given its compelling upside potential of 72.96%. With a focus on..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds